Equity Overview
Price & Market Data
Price: $1.08
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $89,217,720
Volume: 0
Performance Metrics
1 Week: 1.89%
1 Month: -3.57%
3 Months: -18.18%
6 Months: -43.75%
1 Year: -38.98%
YTD: -15.62%
Company Details
Employees: 22
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.